Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZURE-LDL Phase III Study of AZD0780 in ASCVD or High-Risk Patients
jRCT2031250173Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in dyslipidemia and atherosclerotic disease comparing AZD0780 with Placebo (2 arms). Primary endpoint: Relative change in LDL-C from baseline to 12 weeks. Started Jul 2025; status: active, not recruiting.
02
Drugs
laroprovstat
03
Conditions
dyslipidemiaatherosclerotic disease
Beyond the preview
Go deeper on jRCT2031250173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250173.